Refrences.
  1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [27/Feburary/ 2025].
  2. Campbell SC, Lane BR. Malignant renal tumors. Campbell-Walsh Urology. 2012:1413-74.
  3. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Reviews in urology. 2002;4(4):163.
[4] Edge SB, American Joint Committee on Cancer AC. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2010.
[5]  ”Kidney Cancer”. National Cancer Institute. 2019. Archived from the original on 15 August 2020. Retrieved 8 June 2019.
[6] Cairns P. Renal cell carcinoma. Cancer biomarkers. 2011 Jan 1;9(1-6):461-73.
[7] Lee J, Chae HK, Lee W, Nam W, Lim B, Choi SY, Kyung YS, You D, Jeong IG, Song C, Hong B. Comparison of prognosis in types 1 and 2 papillary renal cell carcinoma and clear cell renal cell carcinoma in T1 stage. The Korean Journal of Urological Oncology. 2018 Dec 28;16(3):119-25.
[8]  ”Kidney Cancer - Risk Factors and Prevention”. Cancer.Net. 2012-06-25. Archived from the original on 2019-12-02. Retrieved 2019-12-02.
[9]  ”Hereditary Papillary Renal Carcinoma”. Cancer.Net. 2012-06-25. Retrieved 2020-04-08.
  1. Mancilla‐Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma. A clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976 Dec;38(6):2469-80.
  2. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000 Aug 1;89(3):604-14.
  3. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. The American journal of surgical pathology. 2008 Dec 1;32(12):1822-34.
  4. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. The American journal of surgical pathology. 2003 May 1;27(5):612-24.
  5. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, Venturina MD, Deshpande A, Menon M. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. The American journal of surgical pathology. 2002 Mar 1;26(3):281-91.
  6. Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Annals of surgical oncology. 2004 Jan;11:71-7.
  7. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. The Journal of urology. 2010 Apr;183(4):1309-16.
  8. Gontero P, Ceratti G, Guglielmetti S, Andorno A, Terrone C, Bonvini D, Faggiano F, Tizzani A, Frea B, Valente G. Prognostic factors in a prospective series of papillary renal cell carcinoma. BJU international. 2008 Sep;102(6):697-702.
  9. Ljungberg B, Alamdari FI, Stenling R, Roos G. Prognostic significance of the Heidelberg classification of renal cell carcinoma. European urology. 1999 Dec 1;36(6):565-9.
  10. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1997 Jun 1;10(6):537-44.
  11. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Human pathology. 2001 Jun 1;32(6):590-5.
  12. Zeng Q, Luo S, Chen L, Chen L, Chen J. Bladder metastasis from type 2 papillary renal cell carcinoma: A case report. Oncology Letters. 2023 May 5;25(6):270.
  13. Kosaka T, Mikami S, Miyajima A, Oya M. Metastatic type-2 papillary renal cell carcinoma responded to interleukin-2 therapy: case report. Clinical and experimental nephrology. 2008 Apr;12:155-8.
  14. Tomlinson, IP, Alam, NA, Rowan, AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410
  15. Schmidt, LS, Junker, K, Nakaigawa, N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-2350
  16. Durinck, S, Stawiski, EW, Pavía-Jiménez, A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet 2015;47:13-21
  17. Harrison WJ, Andrici J, Maclean F, Madadi-Ghahan R, Farzin M, Sioson L et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. American Journal of Surgical Pathology. 2016 May;40(5):599-607. doi: 10.1097/PAS.0000000000000573
  18. Kapila V, Kalra AG, Stockman DL, Kapila-Kalra V. A non-hereditary case of hereditary leiomyomatosis and renal cell carcinoma syndrome. Cureus. 2021 Feb 15;13(2).
  19. Xia S, Lin Y, Lin J, Li X, Tan X, Huang Z. Increased expression of TICRR predicts poor clinical outcomes: a potential therapeutic target for papillary renal cell carcinoma. Frontiers in Genetics. 2021 Jan 11;11:605378.
  20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. New England Journal of Medicine. 2016 Jan 14;374(2):135-45.
  21. Pal SK, Ali SM, Yakirevich E, et al. Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling. Eur Urol 2018
[31]
[32] Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma [Figure presented]. Eur Urol 2019.
[33] Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011.
[34] Woldu SL, Weinberg AC, RoyChoudhury A, et al. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol 2014.
[35] Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: Analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003.
Park JH, Kim YO, Park JH, et al. Comparison of acquired cystic kidney disease between hemodialysis and continuous ambulatory peritoneal dialysis. Korean J Intern Med 2000.
Shuch B, Hahn AW, Agarwal N. Current treatment landscape of advanced papillary renal cancer. J Clin. Oncol. 2017; 35 (26): https://ascopubs.org/doi/10.1200/JCO.2017.74.3328
[38] Sung H, Jiang C, Bandi P, Minihan A, Fidler-Benaoudia M, Islami F, Siegel RL, Jemal A. Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data. The Lancet Public Health. 2024 Aug 1;9(8):e583-93.